Seelos Therapeutics, Inc. (SEEL) |
|
0.6912 -0.001 (-0.12%)
|
03-31 16:00 |
|
Open: |
0.7 |
Pre. Close: |
0.692 |
|
High:
|
0.7147 |
Low:
|
0.67 |
|
Volume:
|
303,195 |
Market Cap:
|
75(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:22:00 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.84 One year: 0.94 |
| Support: |
Support1: 0.57 Support2: 0.48 |
| Resistance: |
Resistance1: 0.72 Resistance2: 0.81 |
| Pivot: |
0.68  |
| Moving Average: |
MA(5): 0.69 MA(20): 0.67 
MA(100): 0.81 MA(250): 0.84 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 72.2 %D(3): 74.4 |
| RSI: |
RSI(14): 48.8 |
| 52-week: |
High: 1.51 Low: 0.47 |
| Average Vol(K): |
3-Month: 566 (K) 10-Days: 495 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SEEL ] has closed below upper band by 41.1%. Bollinger Bands are 71.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.72 - 0.72 |
0.72 - 0.72 |
|
Low:
|
0.66 - 0.67 |
0.67 - 0.67 |
|
Close:
|
0.68 - 0.69 |
0.69 - 0.7 |
|
Company Description |
|
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. |
Headline News |
Thu, 30 Mar 2023
Should You Buy Seelos Therapeutics Inc (SEEL) Stock on Thursday? - InvestorsObserver
Fri, 24 Mar 2023
Meta Platforms To Rally Over 32%? Here Are 10 Other Analyst ... - Investing.com UK
Wed, 15 Mar 2023
What is the Market's View on Seelos Therapeutics Inc (SEEL ... - InvestorsObserver
Tue, 14 Mar 2023
SEELOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Sun, 12 Mar 2023
10 Best Psychedelic Stocks to Buy According to Hedge Funds - Yahoo Finance
Wed, 08 Mar 2023
7 Best Psychedelic Stocks to Watch in 2023 - WTOP
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
107 (M) |
| Shares Float |
104 (M) |
|
% Held by Insiders
|
2.9 (%) |
|
% Held by Institutions
|
28.3 (%) |
|
Shares Short
|
5,730 (K) |
|
Shares Short P.Month
|
5,920 (K) |
Stock Financials |
|
EPS
|
-0.63 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.31 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-82.4 |
|
Return on Equity (ttm)
|
-203.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-67 (M) |
|
Levered Free Cash Flow
|
-43 (M) |
Stock Valuations |
|
PE Ratio
|
-1.11 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.16 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.11 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-01-23 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
